13 completed, 1 unknown. 5 Phase 1, 4 Phase 4, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow zolmitriptan: new trials by email Literature Review of zolmitriptan trials Research Report on zolmitriptan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan. Zolmitriptan intranasal., Zolmitriptan oral. - Healthy | Phase 1 | Completed | Parc de Salut Mar | 8 | 2023-07-12 | 2026-05-05 |
| Cocaine and Zolmitriptan Cocaine, Placebo oral capsule, Zolmitriptan - Cocaine Use Disorder | Early Phase 1 | Completed | William Stoops | 12 | 2021-10-15 | 2025-08-05 |
| Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0 - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 48 | 2021-06-24 | 2021-09-17 |
| A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2019-05-29 | 2021-11-18 |
| Efficacy and Safety of Zolmitriptan by Sublingual Administration zolmitriptan by sublingual administration, zolmitriptan by oral - Cluster Headache | Phase 4 | Unknown | Xijing Hospital | 71 | 2018-01-01 | 2017-12-19 |
| Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department Paracetamol, Zolmitriptan - Acute Migraine Headache | Phase 4 | Completed | Pamukkale University | 200 | 2016-01-01 | 2017-05-09 |
| Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults zolmitriptan, CVT-427 (zolmitriptan inhalation powder), - Migraine | Phase 1 | Completed | Acorda Therapeutics | 21 | 2015-11-01 | 2016-06-06 |
| Zomig - Treatment of Acute Migraine Headache in Adolescents Placebo, Zolmitriptan - Migraine Headache | Phase 4 | Completed | AstraZeneca | 1653 | 2010-09-01 | 2016-05-18 |
| Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers Rapimelt, [11C]AZ10419369 - Migraine | Phase 1 | Completed | AstraZeneca | 10 | 2010-05-01 | 2010-11-03 |
| Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine Zolmitriptan 5 mg Nasal Spray, Eletriptan 40 mg tablet - Acute Migraine, Migraine Headache | Not applicable | Completed | California Medical Clinic for Headache | 80 | 2008-04-01 | 2011-01-14 |
| Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg - Migraine | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1380 | 2007-02-15 | 2018-10-17 |
| ZAP, US. Zomig for Appropriate for Primary Care Zolmitriptan - Migraine | Phase 4 | Completed | AstraZeneca | 120 | 2004-07-01 | 2009-04-06 |
| Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents Zolmitriptan, Placebo - Migraine | Phase 3 | Completed | Impax Laboratories, LLC | 247 | 2003-09-01 | 2024-10-02 |
| Efficacy and Tolerability of Zolmitriptan Nasal Spray Zolmitriptan, Placebo - Migraine | Phase 3 | Completed | AstraZeneca | 2114 | 2002-09-01 | 2009-04-06 |
Migraine Disorders (11) · Headache (5) · Cluster Headache (1) · Headache Disorders (1) · Pain (1)
AstraZeneca (4) · Zosano Pharma Corporation (2) · Acorda Therapeutics (1) · California Medical Clinic for Headache (1) · Impax Laboratories, LLC (1) · Merck Sharp & Dohme LLC (1) · Pamukkale University (1) · Parc de Salut Mar (1) · William Stoops (1) · Xijing Hospital (1)
United States (6) · Estonia (1) · Finland (1) · Hungary (1) · Latvia (1) · Poland (1) · Serbia (1) · Slovakia (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1)
Don Kellerman, PharmD (2) · Andrew Eisen, MD (1) · Brendan Smyth (1) · Cuneyt Arikan, MD (1) · David B Kudrow, MD (1) · Li Li, MD (1) · Paul Winner (1) · Rohini Chitra (1) · Stephen Kanes (1)
R01DA052203 (1)